Robert Fish - Amer Renal Independent Director
Director
Mr. Robert H. Fish is an Independent Director of the Company. Mr. Fish currently serves as a director and chairman of Genesis Healthcare, Inc. and LifeCare Health Partners, LLC. Mr. Fish has held leadership positions in a wide variety of health care service organizations, including CEO of Skilled Healthcare Group, Inc. prior to its combination with Genesis Healthcare, Inc., Managing Partner of SonomaSeacrest, LLC, Chairman and CEO of Genesis Health Ventures, a predecessor to Genesis, President and CEO of St. Joseph Health System, and President and CEO of Valley Care Health System. Mr. Fishs prior board experience includes serving as chairman of REACH Medical Holdings, serving as the executive chairman of Coram, Inc., and serving as a director of NeighborCare, Inc. Mr. Fish also serves as a member of the board of directors of the St. Helena Hospital Foundation, a philanthropic organization benefiting the St. Helena Hospitals in Napa Valley since 2017.
| Age | 69 |
| Tenure | 7 years |
| Phone | 978 922-3080 |
| Web | www.americanrenal.com |
Amer Renal Management Efficiency
The company has Return on Asset of 4.35 % which means that on every $100 spent on assets, it made $4.35 of profit. This is considered to be average in the sector. In the same way, it shows a return on shareholders' equity (ROE) of 17.51 %, implying that it generated $17.51 on every 100 dollars invested. Amer Renal's management efficiency ratios could be used to measure how well Amer Renal manages its routine affairs as well as how well it operates its assets and liabilities.Amer Renal Assoc has 724.51 M in debt with debt to equity (D/E) ratio of 3.94, meaning that the company heavily relies on borrowing funds for operations. Amer Renal Assoc has a current ratio of 1.03, demonstrating that it is in a questionable position to pay out its financial commitments when the payables are due. Note however, debt could still be an excellent tool for Amer to invest in growth at high rates of return.
Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Kin Yuen | Emerson Radio | 64 | |
| Elizabeth Lempres | Axalta Coating Systems | 60 | |
| Charles Cogut | Air Products and | 73 | |
| Margaret McGlynn | Air Products and | 59 | |
| Steven Chapman | Axalta Coating Systems | 66 | |
| Michael Binney | Emerson Radio | 65 | |
| Carrie McKim | Codexis | N/A | |
| HingYuen Ho | Air Products and | 61 | |
| Samuel Smolik | Axalta Coating Systems | 67 | |
| Kareem Sethi | Emerson Radio | 41 | |
| Dahan Valeria | Supercom | N/A | |
| Thomas Stafford | NL Industries | 90 | |
| Cecil Moore | NL Industries | 81 | |
| Rakesh Sachdev | Axalta Coating Systems | 68 | |
| Chadwick Deaton | Air Products and | 68 | |
| Robert Mclaughlin | Axalta Coating Systems | 63 | |
| Deborah Kissire | Axalta Coating Systems | 63 | |
| Meredith Mendes | NL Industries | 62 | |
| Arie Trabelsi | Supercom | 66 | |
| John Harper | NL Industries | 59 | |
| Susan Carter | Air Products and | 61 | |
Management Performance
| Return On Equity | 17.51 | |||
| Return On Asset | 4.35 |
Amer Renal Assoc Leadership Team
Elected by the shareholders, the Amer Renal's board of directors comprises two types of representatives: Amer Renal inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Amer. The board's role is to monitor Amer Renal's management team and ensure that shareholders' interests are well served. Amer Renal's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Amer Renal's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Syed Kamal, President, Co-Founder, Director | ||
| Thomas Erickson, Independent Director | ||
| Jared Hendricks, Independent Director | ||
| John Jureller, Independent Director | ||
| Robert Fish, Independent Director | ||
| Joseph Carlucci, Chairman of the Board, Chief Executive Officer, Co-Founder | ||
| Michael Boxer, Independent Director | ||
| Jeremy Gelber, Independent Director | ||
| Susanne Clark, Independent Director | ||
| Don Williamson, Chief Operating Officer, Executive Vice President | ||
| Christopher Hocevar, Independent Director | ||
| Mark Herbers, Interim Chief Financial Officer, Interim Chief Accounting Officer |
Amer Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Amer Renal a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 17.51 | |||
| Return On Asset | 4.35 | |||
| Profit Margin | (1.11) % | |||
| Operating Margin | 9.73 % | |||
| Current Valuation | 1.26 B | |||
| Shares Outstanding | 34.54 M | |||
| Shares Owned By Insiders | 9.15 % | |||
| Shares Owned By Institutions | 80.77 % | |||
| Number Of Shares Shorted | 608.63 K | |||
| Price To Earning | 144.04 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Funds Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.
Other Consideration for investing in Amer Stock
If you are still planning to invest in Amer Renal Assoc check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Amer Renal's history and understand the potential risks before investing.
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account |